Navigation Links
Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). EU5 pulmonologists expect robust uptake of Relvar as a first-line LABA/ICS FDC in the treatment of asthma with one-quarter to half of surveyed pulmonologists considering the drug as a first-line maintenance therapy for treatment-naive persistent asthma patients. However, interviewed payers across EU5 countries caution that in order for Relvar to secure premium pricing, superior efficacy data over Seretide (GlaxoSmithKline) would be required. Thus, despite its lower dosing frequency, the existing noninferiority data for Relvar will most likely drive an equivalent price to that of currently available twice-daily LABA/ICS FDCs.

Other key findings from the European Physician and Payer Forum report entitled Asthma in the EU5: What Are the Expectations for Optimal Positioning of New and Emerging Inhaled and Biological Therapies in Market Access Systems?:

  • Market-access hurdles for emerging biologics: Interviewed payers and surveyed pulmonologists across the EU5 view the ability to identify likely responders as a benefit for the emerging anti-IL-5 therapies -- Cinquil (Cephalon/Teva), Bosatria (GlaxoSmithKline) and benralizumab (MedImmune/AstraZeneca). However, payers anticipate the cost of such diagnostic testing could be a hurdle for reimbursement and uptake.
  • Impact of emerging generics and biosimilar omalizumab: Interviewed EU5 payers agree that the use of generic or branded-generic versions of LABA/ICS FDCs, Seretide and Symbicort (AstraZeneca), and biosimilar omalizumab are likely to be promoted. Surveyed pulmonologists indicate that concerns regarding safety and bioequivalency of biosimilar omalizumab to Xolair (Genentech/Novartis) need to be addressed before they would consider prescribing the drug.


Comments from Decision Resources Group Analyst Eun-Jin Yang, Ph.D.:

  • "In these times of austerity, payers across the EU5 emphasize that for an emerging therapy to secure favorable terms in reimbursement and pricing negotiations, the drug has to demonstrate superiority in efficacy in head-to-head trials against an appropriate comparator. Thus, given the non-inferiority efficacy profile in asthma indication, Relvar's pricing will be key for its favorable placement in the treatment guideline and for driving uptake."
  • "Even though payers across the EU5 have only a modest cost-saving expectation for generic LABA/ICS FDCs and for biosimilar omalizumab, they indicate a strong interest in promoting the usage of these agents, particularly for treatment-naive patients. However, they are less enthusiastic for biosimilar omalizumab, likely due to the lack of experience with biosimilars to date which contributes to payer and physician uncertainty regarding biosimilar omalizumab's safety and bioequivalency to Xolair. This could be mitigated by biosimilar omalizumab demonstrating a robust safety and bioequivalency profile compared to Xolair."


About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo -




SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
(Date:11/24/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Piper ... public is welcome to participate in the conference ... Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, Chief ... Eastern Time Webcast: , ...
(Date:11/24/2015)... , 24. November 2015 ... Breathing Pacemaker Systems, ist erfreut, die Berufung ... Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er Fellow ...
(Date:11/24/2015)... COMMACK, N.Y. , Nov. 24, 2015 ... Pacemaker System, is pleased to announce the appointment of ... ... and pediatric cardiology at Children,s Hospital, Uppsala University, Uppsala ... . From 1984-1986, he was a fellow at the ...
Breaking Medicine Technology:
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an ... is being more and more widely heralded as a breakthrough for performing hernia repairs. ... has over traditional laparoscopic surgery is that it can greatly reduce the pain that ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical ... its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this ... Brillianteen has been a treasured tradition for numerous families in the Evanston community. ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):